Wednesday June 23, 2010
Regarding Ferumoxytol (Feraheme)

Ferumoxytol is a newly approved intravenous iron preparation for treatment of the anemia particularly chronic kidney disease (CKD). Because little free iron is present in the preparation, doses of 510 mg have been administered safely in as little as 20 seconds. The most common adverse events with ferumoxytol are at injection site (bruising, pain, swelling, erythema).

Feraheme injection is an aqueous colloidal product that is formulated with mannitol. It is a black to reddish brown liquid, and is provided in single use vials containing 510 mg of elemental iron.

Intravenous ferumoxytol can be safely and rapidly administered, and is more effective than oral iron therapy in increasing hemoglobin levels. The recommended dose of Feraheme is an initial 510 mg IV injection followed by a second 510 mg intravenous injection 3 to 8 days later.